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Background: Pancreatic cancer is one of the most lethal and molecularly diverse malignancies. Repurposing of
therapeutics that target specific molecular mechanisms in different disease types offers potential for rapid
improvements in outcome. Although HER2 amplification occurs in pancreatic cancer, it is inadequately characterized
to exploit the potential of anti-HER2 therapies.
Methods: HER2 amplification was detected and further analyzed using multiple genomic sequencing approaches.
Standardized reference laboratory assays defined HER2 amplification in a large cohort of patients (n = 469) with
pancreatic ductal adenocarcinoma (PDAC).
Results: An amplified inversion event (1 MB) was identified at the HER2 locus in a patient with PDAC. Using
standardized laboratory assays, we established diagnostic criteria for HER2 amplification in PDAC, and observed a
prevalence of 2%. Clinically, HER2- amplified PDAC was characterized by a lack of liver metastases, and a
preponderance of lung and brain metastases. Excluding breast and gastric cancer, the incidence of HER2-amplified
cancers in the USA is >22,000 per annum.
Conclusions: HER2 amplification occurs in 2% of PDAC, and has distinct features with implications for clinical
practice. The molecular heterogeneity of PDAC implies that even an incidence of 2% represents an attractive target
for anti-HER2 therapies, as options for PDAC are limited. Recruiting patients based on HER2 amplification, rather
than organ of origin, could make trials of anti-HER2 therapies feasible in less common cancer types.Background
Pancreatic cancer is the fourth leading cause of cancer
death in western societies, with a 5-year survival rate of
less than 5% [1]. Systemic therapies are only modestly ef-
fective; however, there is emerging evidence that small
groups of patients may respond well to specific treatments
[2,3]. Current therapeutic development is focused on
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reproduction in any medium, provided the orin significant improvements in outcome for several
cancer types (for example, crizotinib for EML4-ALK
fusion-positive non-small cell lung cancer (NSCLC)).
This approach is shifting the traditional organ-based
classification of cancer towards a new molecular tax-
onomy, and creating opportunities to apply therapeutics
for the treatment of cancers originating in other organs
that harbour similar molecular anomalies. Such indica-
tions for extension of existing therapeutics is attractive;
however, specific molecular phenotypes and diagnostic
characteristics are complex and usually inadequately de-
fined [4,5]. The target population for cancers of organs,
apart from where the therapeutic strategy was initially
developed, often occur at low frequency, further adding
to the challenge.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the International Cancer Genome Consortium (ICGC) [6]
and The Cancer Genome Atlas (TCGA) [7] are unveiling a
vast heterogeneity of molecular aberrations in cancer. Pan-
creatic ductal adenocarcinoma (PDAC), the predominant
form of pancreatic cancer, is particularly heterogeneous,
and apart from a few notable exceptions, which have not
been successfully targeted, most genetic aberrations have a
frequency of 2% or less [8-10].
Trastuzumab, a monoclonal antibody that targets the
HER2 receptor, is an effective therapy for HER2-amplified
breast cancer, and was recently extended to the treatment
of HER2-amplified gastric cancer [11]. In addition, border-
line signals have been seen in clinical trials of semi-selected
patients with NSCLC [4], and case reports describe excep-
tional responses to trastuzumab in other cancers with
HER2 amplification, such as cholangiocarcinoma [12]. De-
fining HER2 amplification as a biomarker of trastuzumab
responsiveness is integral to targeting appropriate popula-
tions for therapy. Although HER2 overexpression and amp-
lification has been assessed in PDAC (see Additional file 1),
standardized diagnostic assays have on the whole not been
applied, and the roles of emerging diagnostic approaches
such as genomic sequencing are yet to be explored. As a
consequence, the diagnostic criteria and prevalence of
HER2 amplification in PDAC remain unclear. Although
preclinical studies support potential efficacy of trastuzumab
in PDAC [13,14], clinical trials have been hampered by
non-standardized assays and a consequent lack of focus on
appropriate subgroups [15,16]. With the current poor sur-
vival, low therapeutic responsiveness, and vast molecular
heterogeneity of PDAC, even if a relatively low proportion
were found to be HER2-amplified, targeting by HER2
amplification represents an attractive potential therapy.
In this study, we identified HER2 amplification in
diagnostic specimens of PDAC using single nucleotide
polymorphism (SNP) arrays and whole genome sequen-
cing. We defined the characteristics and prevalence
(2.1%) of HER2 amplification in a large cohort of pa-
tients with resected PDAC using standardized reference
laboratory assays. We found that HER2-amplified PDAC
has an atypical pattern of metastatic spread with a predi-
lection for lung metastasis and local recurrence, rather
than liver metastases. Assessment of HER2 amplification
across 16 cancer types suggested a prevalence of at least
22,000 cases per annum in the USA (excluding breast and
gastric cancer), suggesting that a molecular recruitment
strategy may make it feasible to test anti-HER2 therapies
in less common cancer types.
Methods
Ethics approval
Ethics approval for acquisition of data and biological
material was obtained from the human research ethicscommittee at each participating institution, conducted in
accordance with the National Statement on Ethical
Conduct in Human Research 2007 and the Declaration
of Helsinki. Consent was obtained from prospectively
recruited patients for genomic sequencing through the
Australian Pancreatic Cancer Genome Initiative (APGI)
as part of the ICGC. Consent was waived by Human
Research Ethics Committees for retrospectively ac-
quired data and material under an approved protocol
(see Additional file 2).
Genomic sequencing, copy number, and mRNA
expression analysis
Patients were prospectively recruited to the APGI [17]
for genomic sequencing as part of the ICGC, and details
of sample acquisition and processing have been described
previously [9]. Briefly, samples focused on primary oper-
able non-pretreated PDAC. Tissue was prepared by either
full face frozen sectioning or the ends being excised and
processed in formalin, then representative sections were
reviewed by at least one pathologist to verify presence of
carcinoma in the sample to be sequenced, and to estimate
the percentage of malignant epithelial nuclei in the sample
relative to stromal nuclei. Nucleic acids were extracted
from fresh frozen tumour and normal tissue pairs, and
whole genome and exome sequencing was performed
using a combination of long mate pair and paired-end ap-
proaches. DNA copy number was assessed using specific
microarrays (HumanOmni1-Quad BeadChip, Illumina
Inc., San Diego, CA, USA). Primary tumour mRNA ex-
pression was assayed using human microarrays (HT-12
V4; Illumina) (GEO accession GSE36924). Gene expres-
sion profiles were classified into intrinsic breast cancer
subtypes using the PAM50 classifier [18].
Defining prevalence and diagnostic criteria for HER2
amplification
Formalin-fixed, paraffin wax-embedded diagnostic ma-
terial from a cohort of 469 patients who had undergone
operative resection for PDAC was accrued from 12 insti-
tutions associated with the APGI between 1990 and
2012. Subsets of this cohort have previously been pub-
lished [19,20], and detailed characteristics are presented
(see Additional file 3: Table S2).
HER2 immunohistochemistry (IHC) and in situ hybridization
(ISH) was performed in a national reference HER2 diagnos-
tic testing laboratory. Scoring for HER2 protein expression
and amplification was based on criteria recommended for
breast and gastric carcinoma (Table 1) [21].
aThe criteria used for scoring HER2 by immunohisto-
chemistry and in situ hybridization in PDAC were as fol-
lows. Her2 IHC score criteria (modified from Hofmann
et al [21]): 0, no staining of any pattern or intensity; 1+.
weak discernable membrane staining; 2+, mild to
Table 1 IHC and FISH scoring for the detection of HER2
amplificationa
Her2 IHC
score
IHC scores HER2 FISH
(n = 469) Positive, n = 10 Negative, n = 459
3+ 7 (1.5%) 7 0
2+ 27 (5.8%) 3 24
1+ 59 (12.6%) 0 59
0 376 (80.2%) 0 376
Abbreviations: FISH fluorescence in situ hybridization; IHC
immunohistochemistry; PDAC pancreatic ductal adenocarcinoma.
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strong, complete, or basolateral membrane staining. HER2
ISH criteria: non-amplified, Her2 count <4 and Her2:
cep17 ratio <2; amplified, Her2 count ≥4 and Her2:cep17
ratio ≥2.
Results
In the initial set of 50 patients recruited to the APGI,
SNP arrays detected a case of HER2 amplification
(Figure 1A), with associated high HER2 mRNA ex-
pression (see Additional file 4). HER2 amplification
was verified using standardized laboratory assays currently
used for breast and gastric cancer at an HER2 diagnostic
reference laboratory. This case was analyzed further using
whole genome sequencing, copy number analysis, and
mRNA expression profiling.
Genomic characteristics of HER2-amplified pancreatic
ductal adenocarcinoma
Whole genome and exome sequencing identified several
classes of mutation including single nucleotide variants,
small insertions and deletions (indels), and chromosomal
rearrangements (see Additional file 5). Chromosomal
rearrangements included a region of loss on chromo-
some 18 containing the MAPK4, DCC, SMAD4, and
ELAC1 genes, and three complex amplification regions:
an inverted amplification of a region of chromosome 17,
spanning HER2 and truncating MED1 and TOP2A at
either end (chr17:37,565,271-38,554,848) (Figure 1B),
and two overlapping fold back inversion events on
chromosome 9: a 1.5 Mb event within a 1.9 Mb event,
disrupting UBAP2. Exome sequencing identified 23 som-
atic mutations affecting 21 genes, including KRASp.G12V
and TP53p.Q317, and 2 mutations in both TOP2A and
RYR2 (Figure 1C).
We performed gene set enrichment analysis using all
genes affected by mutation, amplification, copy number
alterations (GISTIC2.0 peaks P < 0.25), and disruptions
caused by structural rearrangements (see Additional
file 6). There were three strong biological themes: 1) genes
from the HER2-amplicon (13 genes; P<1 × 10-7); 2) a broad
cancer theme driven by KRAS, TP53, and EPHA5 (13gene sets; P<0.001); and 3) an immune signature, driven
by type I interferons, IFNA2, INFA6, INFA13 (7 gene
sets; P < 0.001), which are involved in recognition of
viral infection and neoplasia (see Additional file 7).
Intrinsic subtype analysis using expression microarray
data from the APGI cohort (n = 90) [9] classified each
PDAC sample using the PAM50 classifier, which captures
five breast cancer subtypes: HER2-amplified, luminal
A, luminal B, basal, and normal-like [18]. The HER2-
amplified patient with PDAC identified above clustered
with the HER2-amplified intrinsic subtype, with a con-
fidence of 93%. This was driven by high expression of
HER2, GRB7, and FOXA1, and low expression of
KRT17 and MIA (see Additional file 8).
HER2 amplification in pancreatic ductal adenocarcinoma
In order to define the clinical and histopathological char-
acteristics, diagnostic criteria, and prevalence of HER2
amplification in PDAC, we assessed a cohort of 469
patients with resected PDAC using IHC and in situ
hybridization (ISH). IHC for Her2 protein expression
showed 3+ staining in 7 cases (1.5%) (Figure 2A), 2+
staining in 27 (5.8%), 1+ in 59 (12.6%) and no staining in
376 (80.2%) (Table 1). All 7 cases that exhibited Her2 3+
staining were found to be HER2-amplified on silver ISH
and fluorescence ISH (FISH) with 100% concordance
between the two methods (Figure 2B,C). Only 3 of 27
cases that were Her2 2+ on IHC were found to be HER2-
amplified (11%). No cases of 1+ or negative Her2 IHC
were HER2-amplified, and the overall prevalence of HER2
amplification was 2.1% (10 of 469 cases). All the amplified
cases showed a tendency for the HER2 signal to form clus-
ters. One case was found to have intra-tumoral heterogen-
eity by IHC and ISH, with distinct HER2-positive and
HER2-negative areas. As HER2 amplification was only
present when Her2 IHC produced 2+ or 3+ staining, IHC
screening followed by ISH in cases of 2+ and 3+ IHC
staining may be an appropriate and cost-effective ap-
proach for the detection of HER2-amplified PDAC (see
Additional file 9).
Clinical features of HER2-amplified pancreatic ductal
adenocarcinoma
Of the ten patients with HER2 amplified tumours, nine
died of PDAC, and one died of respiratory failure as a
result of chronic obstructive pulmonary disease with no
evidence of cancer recurrence. The pattern of metastatic
relapse of the HER2-amplified cases was characterized
by a lack of liver metastases. None of the eight cases
with a documented site of recurrence had liver metastases
(one patient had recurrence, and for another patient the
site of recurrence was not reported). Of these eight
patients, four had lung metastases (one of whom also had
brain metastases (Figure 2D-F), and two also had local
Figure 1 (See legend on next page.)
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Figure 1 HER2-amplified pancreatic ductal adenocarcinoma. (A) Single nucleotide polymorphism (SNP) array showing amplification on
chromosome 17 containing the HER2 locus (boxed). (B) Inverted amplification on chromosome 17, spanning HER2 and truncating MED1 and
TOP2A at either end (chr17:37,565,271-38,554,848). (C) Circos plot showing mutations and structural rearrangements of patient 9 (Table 2). Genes
with non-silent substitutions are shown on the outer wheel. The SNP array data are shown on the subsequent plots (copy number predictions
and B-allele frequency of probes). Structural rearrangements are indicated with lines inside the circle: deletions (green), inversions (yellow), intra-
chromosomal rearrangements (blue), foldback inversions (light orange), and amplified inversions (dark orange). Genes with structural variation are
shown in blue if deleted and green if interrupted.
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in one patient), while the remaining four patients had
peritoneal and local recurrences only, although imaging of
the thorax was not performed in two of these patients
(Table 2). The higher prevalence of lung metastasis (in the
absence of liver metastases) in HER2-amplified tumours
was significantly different to that of non-HER2-amplified
tumours (P = 0.0022; Table 3), as was the rate of recur-
rence at any site without liver metastases (P = 0.0028;
Table 3). HER2 amplification was not associated with
any other clinicopathological characteristics such as age
(P = 0.5467), sex (P = 0.7520), tumour stage (P = 0.4495),
grade (P = 0.1259), or size (P = 0.4695), or disease-specific
survival (P = 0.2502; Table 3). Histopathologically, there
were no specific features to distinguish HER2-amplifiedFigure 2 Clinicopathological features of HER2-amplified pancreatic du
showing 3+ staining, and corresponding HER2 amplification on (B) silver an
(Table 2) showing (D) cerebral and (E) lung metastases, and (F) absence oftumours from non-HER2-amplified tumours. All HER2-
amplified cases were moderately differentiated, and
most had a diffuse or at least focally macroglandular
architecture.
Since the completion of this study, we have begun
prospectively screening patients with PDAC for HER2
amplification using this diagnostic approach, and identi-
fied a further two individuals (of eleven) with HER2
amplification. The first was a primary resected cancer
with no evidence of recurrent disease to date at 6 months.
Subsequently, whole genome sequence analysis on this
patient’s tumour confirmed mutation in KRAS p.G12V. The
second patient had an atypical pattern of metastatic dis-
ease at diagnosis, with a small primary pancreatic tumour
on imaging, histologically confirmed peritoneal disease inctal adenocarcinoma (PDAC). (A) Her2 immunohistochemistry
d (C) fluorescence in situ hybridization. Imaging results of patient 9
liver metastases.
Table 2 Clinicopathological characteristics of HER2-amplified PDAC
Patient Her2 IHC
score
HER2
ratio
HER2
count
Overall survival
(months)
Cause of
death
Pattern of recurrence Comments
Lung Brain Liver Local Peritoneal
1a 3+ 2.45 6 13.6 PDAC - ND - + + Laparotomy showed peritoneal and local
recurrence
2 3+ 7.5 13 43.5 COPD - ND - - - CT at 43 months showed no recurrence
3 3+ 4.12 10 5.0 PDAC - ND - + - Local recurrence
4b 2+ 2.5 5.4 36.5 PDAC + ND - + + Ascites/pleural effusions, no liver
metastases on CT
5 3+ 4.38 8.1 18.6 PDAC ND ND ND ND ND Site not documented
6 2 3.56 7 10.1 PDAC ND ND - + ND R2 resection
7 3+ 2.7 4.5 41.6 PDAC ND ND - + + No liver metastases on CT; peritoneal
recurrence
8 2+ 5.32 9 10.9 PDAC + ND - + - No liver metastases on CT
9c,d 3+ 2.95 6.2 35.0 PDAC + + - - - No liver metastases on CT
10e 3+ 2.86* 6.3 27.0 PDAC + ND - - - No liver metastases on CT
Abbreviations: + present; - absent; COPD chronic obstructive pulmonary disease; CT computed tomography; FISH fluorescence in situ hybridization; IHC
immunohistochemistry; ND not determined; PDAC pancreatic ductal adenocarcinoma.
aReceived adjuvant 5-fluouracil.
bReceived adjuvant gemcitabine.
cOnly case 9 received palliative chemotherapy (gemcitabine + erlotinib) and also received adjuvant gemcitabine.
dCase that was whole genome sequenced.
eCase 10 showed heterogeneous staining.
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unusual pattern of disease, PDAC was verified using a
targeted exome panel of tissue from this patient’s peri-
toneal disease, which showed mutations in KRAS p.G12V
and SMAD4, further supporting the diagnosis of PDAC.HER2 amplification in other cancer types
The low prevalence of HER2 amplification in PDAC
and many other cancer types makes clinical trials chal-
lenging. Analysis of genomic sequence data for 16 other
cancer types (by TCGA, ICGC and other large-scale
genomic efforts) identified an incidence of 0.5% to 13%,
which equates to over 54,000 new cases of HER2-ampli-
fied cancers per year in the USA alone (see Additional
file 10). Excluding breast and gastric cancer, we estimate
an incidence in excess of 22,000 HER2 amplified cancers
per annum. Recruiting patients based on HER2 amplifi-
cation rather than organ of tumour origin would make
trials of anti-HER2 therapies feasible in less common
cancer types. In order to identify these 22,000 patients,
740,000 patients would need to be screened using IHC,
and of these, all 2+ and 3+ IHC cases (~8%) would re-
quire validation using ISH. This approach may circum-
vent the challenges of previous clinical trials based on
organ of origin recruitment, in which there have been
mixed results but some efficacy in individuals (see
Additional file 11). An orthogonal approach by which a
primary molecular classification is used and patients
are sub-classified based on organ of origin may be
more tractable.Discussion
In this study, we found that HER2-amplified PDAC has
a prevalence of 2%, is detectable using contemporary
genomic approaches, is associated with a clinical pheno-
type characterized by metastatic spread predominantly
to the lungs and peritoneum with local recurrence, and
can metastasize to the brain but tends to avoid the liver.
It bears molecular similarities to HER2-amplified breast
cancer, and is yet to be adequately assessed for potential
responsiveness to anti-HER2 therapy. Multiple studies in
large cohorts have shown that HER2-amplified breast
cancers more commonly metastasize to the lung and the
brain [22]. In PDAC, clinical trial data indicate that the
first site of distant metastases occurred most commonly
in the liver (50%), and occurred in the lung in 9% of the
cases [23]. Autopsy studies have reported that 80% of
distant metastases are to the liver, which occurred either
alone or in combination with peritoneal and or lung
metastases, while metastases sparing the liver made up
the rest, and occurred in the peritoneum, lung, adrenal
glands, and lymph nodes [24]. Cerebral metastases were
not found in these studies. In our cohort of 469 patients,
the incidence of lung metastases without liver metasta-
ses was 8%, comparable to previous studies. We detected
only one case with brain metastases (0.2%), although
only this single patient was investigated specifically for
brain metastases. If we include all 10 HER2-amplified
cases with documented metastatic disease, none had
evidence of liver metastases (P = 0.0028), and the rate of
lung metastases was 50% (P = 0.0022). These data
suggest that HER2-amplified PDAC may have a distinct
Table 3 Clinicopathological characteristics of HER2 amplified and HER2 non-amplified cases
Clinicopathological characteristics Total cohort,
n = 469
HER2 amplification P-value
Amplified, n = 10 Non-amplified, n = 459
Sex, n (%)
Male 241 (51) 6 (60) 220 (51) 0.7520b
Female 228 (49) 4 (30) 210 (49)
Age, years
Mean 66 64 66 0.5467c
Median 68 69.5 67.5
Range 28 to 88 47 to 73 28 to 87
AJCC stage, n (%)
1a 17 (3.6) 1 (10) 16 (3.5) 0.4495d
1b 25 (5.3) 1 (10) 24 (5.2)
2a 132 (28.1) 3 (30) 129 (28)
2b 279 (59.5) 4 (40) 275 (60)
4 16 (3.4) 1 (10) 15 (3)
T stage, n
T1 32 1 31
T2 64 2 62
T3 372 7 365
T4 1 0 1
N stage, n
N0 180 6 174
N1 289 4 185
AJCC grade, n
1 (well differentiated) 36 0 36 0.1259d
2 (moderately differentiated) 305 10 295
3 (poorly differentiated) 125 0 125
4 (undifferentiated) 3 0 3
Tumour size, mm
<=20 105 3 102 0.4695b
>20 364 7 357
Vascular invasion, n
Present 222 2 220 0.1106b
Absent 247 8 239
Perineural invasion, n
Present 339 8 331 0.7336b
Absent 130 2 128
Tumour location, n
Head 381 9 372 0.6961b
Others 88 1 87
Margins
Clear 301 7 294 1.0000b
Involved 168 3 165
Chou et al. Genome Medicine 2013, 5:78 Page 7 of 11
http://genomemedicine.com/content/5/8/78
Table 3 Clinicopathological characteristics of HER2 amplified and HER2 non-amplified cases (Continued)
Outcome
Follow-up, months 0.03 to 240 5.0 to 43.6 0.03 to 240 1.0000b
Median follow-up, months 16 23 16
Death: PDAC 369 8 361
Death: other 32 2 30
Death: unknown 16 0 16
Alive 49 0 49
Lost to follow-up 3 0 3
Cancer-specific survival, mean ± SD
Length, months 20 ± 19.43 28 ± 19.65 20 ± 19.55 0. 2502c
Recurrence
Present 261 8 253
Absent 78 1 77
Unknown 130 1 129
Pattern of recurrence, n (% of total n)
Lung without liver metastasis 22 (8.4% of 261) 4 (50% of 8) 18 (7.1% of 253) 0.0022b
Any recurrence without liver metastasis 127 (49% of 261) 8 (100% of 8) 119 (47% of 253) 0.0028b
Adjuvant therapy, n
Yes 175 3 172
No 289 7 282
Unknown 5 0 5
AJCC, American Joint Committee on Cancer; PDAC, pancreatic ductal adenocarcinoma.
aAJCC Cancer Staging Manual, seventh edition.
bFisher’s exact test.
cUnpaired t-test.
dχ2 test.
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determined by physical factors such as portal blood flow,
but by the pathophysiology of disease.
These findings have significant clinical implications.
First, the detection of small lung nodules should not
delay the diagnosis of metastatic disease originating in
the pancreas or at relapse if the liver and other sites are
clear, particularly in known HER2-amplified cases. Second,
if an individual is known to have an HER2-amplified
PDAC, then monitoring for disease progression in non-
traditional sites such as the lung and the brain, with
vigilance for neurological symptoms may be prudent.
Finally, there is potential for anti-HER2 therapies in
this subset of patients.
In situ hybridization studies in our reference laboratory
identified HER2 amplification only in PDACs with high
protein expression by IHC (score 2+/3+). Therefore, a rea-
sonable and cost-effective approach to universal HER2
screening is to initially test all cases with IHC and then
perform secondary ISH testing only on cases with 2+/3+
staining, as was initially performed for breast cancer.
Using this approach, 8% of PDAC (2+ and 3+ cancers) willrequire HER2 ISH assessment, and of these one-quarter
will be amplified.
In the current study, in-depth genomic analysis, apart
from HER2 amplification, did not reveal any features
that are atypical of PDAC, with mutations of KRAS and
TP53 and loss of SMAD4 found, although the inherent
heterogeneity of PDAC makes it difficult to draw conclu-
sions about the other mutations detected. mRNA expres-
sion profiles clustered with HER2-amplified breast cancer,
suggesting that HER2 may be an important driver of
carcinogenesis in this subgroup of PDAC.
It is interesting to note that all three HER2-amplified
cases with available genomic data harboured the KRASp.
G12V mutation. This mutation is less common than the
p.G12D mutation, and accounts for 32% of KRAS muta-
tions in PDAC versus 40% for p.G12D [9]. Given the
small numbers of HER2-amplified cases, further studies
of larger cohorts will be required before it can be deter-
mined if this association is sufficiently robust to be used
diagnostically or targeted therapeutically.
Two clinical trials have assessed targeted trastuzumab
therapy in PDAC [15,16]. Both are single arm phase II
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capecitabine [16]. Although the latter performed HER2
FISH for 2+ expressing cases, the former did not, and
neither verified the 3+ IHC cases by FISH. In addition,
these were not standardized assays performed in reference
laboratories, and resulted in a HER2 positive rate of over
10%. This likely overestimation underpowered the trials by
over 80%, making a negative result uninterpretable.
Conclusion
HER2 amplification occurs in 2.1% of PDAC cases, and
is associated with an atypical pattern of metastatic dis-
ease. A number of cancers of different organs including
NSCLC, ovarian cancer, cholangiocarcinoma, and PDAC
have well-defined low-prevalence HER2 amplification.
Testing anti-HER2 therapies may not be feasible in organ
groups because of this low prevalence and the likely het-
erogeneous response rates. However, these studies could
be approached using novel adaptive clinical trials testing
personalized therapeutic strategies (for example,: BATTLE
[25], I-SPY [26], FOCUS 4 [27] and IMPaCT [3]), or using
a molecular taxonomy or ‘biotype’ that recruits HER2-
amplified cancers irrespective of the organ in which the
tumour arises (often referred to as ‘basket’ trials) [28], with
specific attention to diagnostic criteria for patient recruit-
ment, particularly as more effective anti-HER2 therapies
emerge.
Additional files
Additional file 1: Table S1. Literature reports of Her2 positive rate in
pancreatic ductal adenocarcinoma by immunohistochemistry and in situ
hybridization techniques.
Additional file 2: Supplementary methods.
Additional file 3: Table S2. Clinico-pathological characteristics of the
cohort.
Additional file 4: Figure S1. HER2 mRNA expression relative to cohort.
Additional file 5: Table S3. Single nucleotide variations (SNVs) and
small insertions or deletions (indels) within a patient with HER2
amplification, identified by whole exome sequencing, in MAF format.
Table S4. Single nucleotide variations (SNVs) and small insertions or
deletions (indels) annotated and compared with data from dbSNP,
COSMIC, TCGA Breast, Biankin et al. [9] and Jones et al. [10]. Non-
synonymous mutations were assessed for functional effects by two
algorithms, Polyphen2 and SIFT; scores close to 1.0 and 0.0, respectively,
are predicted to be probably damaging. These data have already been
imported into COSMIC, thus many of the COSMIC identification numbers
are unique only to this patient. Table S5: Genes affected by structural
variation, as determined by whole genome sequencing of tissue from a
patient with HER2 amplification. Table S6: Structural and copy number
aberrations in a patient identified with HER2 amplification. Listed here are
the genes affected by structural variation (SV) as determined by whole
genome sequencing, or copy number altered, as determined by single
nucleotide polymorphism (SNP) array analysis. Genes of interest were
defined as those genes affected by SV that were expected to have a
functional effect (that is, genes that were truncated, amplified (but not
duplicated) or deleted); genes whose copy number was found by SNP
array analysis to be greatly altered, that is, reduced to 0, or the
algorithm’s maximum of four copies (see Methods); and genes that wereaffected by copy number variation and that overlapped the statistically
significant copy number altered regions, as determined by GISTIC 2.0
analysis (see Biankin et al., [9]), reported here by their q-value.
Additional file 6: Table S7. Genomic alterations within a patient
identified with HER2 amplification. Genes of interest were defined as
those affected by non-synonymous single nucleotide variation (SNV);
small insertions or deletions (see Additional file 5: Table S3); genes
affected by structural variation (SV) as determined by whole genome
sequencing, or copy number variation (CNV) as determined by SNP array
analysis (see Additional file 5: Table S6).
Additional file 7: Table S8. MSigDB analysis of all genes affected by
mutation, tructural variation (SV) and copy number variation (CNV) (from
Additional file 6: Table S7).
Additional file 8: Figure S2. Gene expression profiles from 90
pancreatic cancer primary tumors, classified into five intrinsic breast
subtypes by the PAM50 classifier. The HER2-amplified patient is
highlighted by a white box; genes overexpressed or underexpressed in
this patient are highlighted in red and green, respectively.
Additional file 9: Figure S3. Algorithm for diagnostic testing for HER2
amplification.
Additional file 10: Table S9. Incidence of and deaths from HER2-
amplified cancers in the USA. Extrapolating from the frequency of HER2
amplifications identified from current projects from The Cancer Genome
Atlas (TCGA) and our own International Cancer Genome Consortium
(ICGC) pancreatic ductal adenocarcinoma (PDAC) project, with the
estimated number of new cancer cases in the USA in 2012. From the
1.37 million expected cases, we would expect 54,000 (3.94%) new cases
of HER2-amplified cancer. Excluding breast and stomach, for which HER2
diagnostic assays are common practice, we expect 740,000 new cases,
22,000 of which will be HER2-amplified. Extrapolating from the number of
immunohistochemistry (IHC) and in situ hybridization (ISH) assays to
identify HER2-amplified PDAC (see Additional file 9: Figure S3), to identify
these additional cases, we would expect to perform 742,000 IHC and
117,000 FISH assays, of which 22,000 will be confirmed (that is, will have
IHC staining of 2+ or 3+ and be ISH-positive). Figure S4. Prevalence of
HER2 amplification (≥4 copies) in cancer: data from The Cancer Genome
Atlas (TCGA), via the cBio portal, and the International Cancer Genome
Consortium (ICGC) [9].
Additional file 11: Table S10. Clinical trials of HER2-amplified cancers,
excluding breast and stomach (gastric) cancers.Abbreviations
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